

Alteplase increased the likelihood of symptomatic intracranial haemorrhage. Type 2 parenchymal haemorrhage within 7 days occurred in 231 (6·8%) of 3391 patients assigned alteplase versus 44 (1·3%) of 3365 assigned control (OR 5·55, 95% CI 4·01–7·70; p<0·0001) and SITS-MOST criteria type 2 parenchymal haemorrhage within 36 h occurred in 124 (3·7%) of 3391 versus 19 (0·6%) of 3365 (OR 6·67, 95% CI 4·11–10·84; p<0·0001). Fatal type 2 parenchymal haemorrhage within 7 days occurred in 91 (2·7%) patients assigned alteplase versus 13 (0·4%) assigned control (OR 7·14, 95% CI 3·98–12·79; p<0·0001). The proportional increase in risk of fatal intracranial haemorrhage was much the same, irrespective of treatment delay, age, or severity (p$_{interaction}$>0·7 for all), but the absolute increase did not increase the



	Intervention population	Control population
Symptomatic intracranial haemorrhage	4·4% (28/634)	4·5% (28/623)
Parenchymal haematoma type 2	5·1% (32/629)	5·3% (34/641)
Mortality	15·3% (32/633)	18·9% (122/646)

Data show the proportion of patients with outcome (n/N), unless otherwise

Table 4: Safety outcomes at 90 days

Figure 2: Scores on the modified Rankin Scale at 90 days

Distribution of scores at 90 days in the intervention and control groups in the overall trial population (A) and for patients treated with, or not given, tissue plasminogen activator (B). Distributions for other subgroups shown in appendix (p 2).

Seven studies used modified TICI scores to evaluate successful recanalization (modified TICI score of 2b–3) only in the endovascular treatment arm, and all focused on IVT+MT. Our traditional meta-analysis yielded a pooled rate of successful recanalization for IVT+MT of 75% (95% CI, 65%–83%; Figure XIC in the Data Supplement).









Emberson et al. 2014
Alteplase
meta-analysis

Goyal et al. 2016
HERMES
thrombectomy
meta-analysis

SAMueL-1 survey
Pre-stroke
patient statistics

Hui et al. 2020
Recanalisation
meta-analysis

de la Ossa Herrero
et al. 2013
RACE scale (predict LVO
based on NIHSS)

Lees et al. 2010
Intravenous alteplase
meta-analysis

Sanity checks:

Non-Large-Vessel Occlusion

P(mRS 0 - 1|alteplase and OTT = x)	0.6343-0.00000005x² - 0.0005x; minimum value = 0.4622

Holodinsky et al. 2018
Pre-hospital transport model



Fransen et al. 2016
MR CLEAN clinical trial on recanalisation



NIHSS†		
0–5	304 (20%)	308 (20%)
6–10	422 (28%)	430 (28%)
11–15	306 (20%)	295 (19%)
16–20	270 (18%)	273 (18%)
>20	213 (14%)	213 (14%)

IST-3 collaborative group
et al. 2012
Thrombolysis meta-analysis